Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01450449 : Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme
PhasePhase 3
AgesMin: 50 Years Max: N/A
Inclusion Criteria:

- Histopathologically confirmed newly diagnosed glioblastoma multiforme (GBM, WHO grade
IV). The histological diagnosis must have been made locally after biopsy or
neurosurgical tumour resection.

- Initial surgery/biopsy at diagnosis performed < 6 weeks (42 days) prior to

- Patient's age is 50 years or older.

- Karnofsky performance status is 50% or higher.

- Patients may have received and continue to receive corticosteroids, but they have to
be on a stable or decreasing dose for at least 14 days prior to randomization.

- Patients must not have received prior chemotherapy or radiotherapy.

- Patient is able (i.e. sufficiently fluent) and willing to complete the quality of
life questionnaires in either English or any other language the questionnaire is
officially translated into. The baseline assessment (prior to start of radiotherapy)
must already have been completed. Inability (illiteracy, loss of sight, or other
equivalent reason) to complete the questionnaires will not make the patient
ineligible for the study. In centres where patients are not able to read or write,
proxy interviews will be conducted in-person or via telephone by the nurse at that
particular centre.

- Patient consent must be obtained according to local institutional policy.
It will be the responsibility of the local participating investigators to obtain
the necessary local clearance, and to indicate in writing to the IAEA Study
Coordinator that such clearance has been obtained, before the trial can commence
in that centre. A copy of the initial full board ERB approval and approved consent
form must be sent to the Project Officer at IAEA. The patient must sign the consent
form prior to randomization or registration.

- Patients must be accessible for treatment and follow-up. Investigators must assure
themselves the patients randomized on this trial will be available for complete
documentation of the treatment, adverse events, and follow-up.

- Protocol treatment is to begin within 2 weeks of patient randomization.

Exclusion Criteria:

- Patients with a history of other malignancies, except: adequately treated
non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other
solid tumours curatively treated with no evidence of disease for 3 or more years.

- Patients with a serious active infection or other serious underlying medical
conditions that would impair the ability of the patient to receive protocol treatment
or comply with protocol.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557